Shots:
- Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product
- Merck to receive an exclusive license to develop, manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea
- Efinopegdutide is a GLP-1/glucagon receptor dual agonist, activating the both the GLP-1 and glucagon receptors, currently being evaluated in multiple P-I & P-II studies, including for the treatment of severely obese individuals with/without T2D
Click here to read full press release/ article | Ref: Merck & Co. | Image: PharmaShots
